UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer
Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology
Ms. Barrett will present at the 37th Annual J.P.
Ms. Barrett brings over 30 years of unique experience across oncology, specialty care, surgical franchises, and consumer marketing in multiple geographic regions. Her demonstrated expertise in pharmaceutical development and commercialization of oncology products will be critical as UroGen transforms into a leading commercial-stage entity and delivers potentially paradigm-shifting products to oncology patients in the urological setting.
“Liz has proven to be an exceptional leader with a well-established
track record in oncology and the vision and experience to lead UroGen as
it prepares for the expected launch of UGN-101, the Company’s first
potential product, in 2019,” said Arie Belldegrun, M.D., FACS, Chairman
of the Board of UroGen. “Through the persistence and dedication of
Ms. Barrett was CEO of Novartis Oncology and a member of the
“I’ve built a career with some of the best companies in the industry and
have had the opportunity to be entrepreneurial within each of those
positions. This is an opportune time to take that experience and apply
it to a smaller biotech company on the cusp of transformation,” said Ms.
Barrett. “UroGen is well positioned to firmly establish the viability of
its RTGel platform as the Company completes its first NDA submission to
“I’ve had the great honor of leading UroGen through its early stages of
development, its initial public offering, completed enrollment of our
first pivotal trial, and now, initiation of our first rolling NDA
UroGen recently announced its initiation of the UGN-101 Rolling NDA
Submission to the
A live audio webcast of the J.P. Morgan presentation will be available on the Investors section of UroGen’s website www.urogen.com. A replay of the webcast will be available on the website for approximately 30 days.
Forward Looking Statements
This press release contains forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995,
including with respect to the timing of submission and completion of a
rolling NDA for UGN-101, the potential regulatory approval and
commercialization of UGN-101, and the effects of Ms. Barrett joining
Director, Corporate Communications & Investor Relations